• You need to sign in or sign up before continuing.
Close
Announcements
Projects
Orgs
Project Post
Articles 130
Votes 0
Endpoints News

Authors 22

Max Gelman
Tyler Patchen
Lei Lei Wu
Amber Tong
John Carroll
Zachary Brennan
Kyle LaHucik
Nicole DeFeudis
Paul Schloesser
Katherine Lewin
Beth Snyder Bulik
Katherine
Andrew Dunn
Drew Armstrong
Ryan Cross
Jared Whitlock
Reynald Castañeda
Jaimy Lee
Ayisha Sharma
Anna Brown
Lia DeGroot
ENDPOINTS
A longtime tracker on pharma R&D productivity takes a post-pandemic plunge back to a bleak reality - Endpoints News
>2y
Amgen launches the first US Humira biosimilar at two different list prices - Endpoints News
>2y
Lilly enters ripe BTK field with quick FDA nod in mantle cell lymphoma - Endpoints News
>2y
Harris Poll breaks down #JPM23 conference's hottest topics and popular people among industry experts - Endpoints News
>2y
FDA offers new draft guidance on cancer drug dose optimization with overhaul of maximum tolerated dose paradigm - Endpoints News
>2y
Moderna jumps into pivotal pack with promising RSV data as big rivals face off in megablockbuster race - Endpoints News
>2y
Corrected: Facing decades in prison, two biotech leaders charged with wire and securities fraud, lying to investigators - Endpoints News
>2y
Prometheus moves to raise cash hours after PhII data leads to stock surge - Endpoints News
>2y
Former BridgeBio exec launches new anti-inflammatory biotech with $169M, but is mum on what exactly it's doing - Endpoints News
>2y
Verve reveals letter from FDA that lays out conditions to lift base editing trial hold - Endpoints News
>2y
Sanofi and Amgen are bringing cash to cover the table stakes for the Horizon M&A game - Endpoints News
>2y
Days after reporting PhIII failure, GSK pulls BCMA drug from US market — but it's not giving up entirely yet - Endpoints News
>2y
Roche cuts PhII eye disease program, one day after another biotech flopped in same indication - Endpoints News
>2y
Updated: Not known for gene therapy plays, Eli Lilly acquires hearing loss startup Akouos for $487M plus CVR - Endpoints News
>2y
NeuBase lays off 60% of employees as it swaps out antisense focus for gene editing tech endorsed by George Church - Endpoints News
>2y
A year after debuting with $500M, Bob Nelsen's Really Big Neuroscience Company raises a really not-as-big Series B - Endpoints News
almost3y
Advocates, experts cry foul over Amylyx's new ALS drug, citing issues with price, PhIII commitment - Endpoints News
almost3y
As lead drug flopped and AbbVie collab dissolved, cancer biotech resorts to buying rare disease company - Endpoints News
almost3y
Novo Nordisk joins Novartis, Roche in NLRP3 arena, betting $70M cash on NASH, cardiometabolic uses - Endpoints News
almost3y
Biogen, Eisai refresh amyloid hypothesis with PhIII showing Alzheimer's med slows cognitive decline - Endpoints News
almost3y
Bluebird lands another rare disease gene therapy OK — but there are a few caveats to note - Endpoints News
almost3y
FDA again finds Amylyx's ALS data lacking ahead of unusual second adcomm, while stressing dire need for treatments - Endpoints News
almost3y
As Novo Nordisk begins PhII sickle cell trial, it snags a later-stage blood disorder drug in $1.1B Forma buy - Endpoints News
almost3y
With cash in the bank and an eye on Europe, Neurocrine buys out a London-based outfit - Endpoints News
almost3y
After wrestling with the Sandoz problem for several years, Vas Narasimhan settles on a spinout - Endpoints News
almost3y